tiprankstipranks
Trending News
More News >

ASKA Pharmaceutical Reports FY2024 Financial Results with Strategic Dividend Increase

Story Highlights
ASKA Pharmaceutical Reports FY2024 Financial Results with Strategic Dividend Increase

Don’t Miss TipRanks’ Half-Year Sale

ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) has shared an update.

ASKA Pharmaceutical Holdings Co., Ltd. reported its consolidated financial results for FY2024, showing a slight increase in net sales by 2.1% to 64,139 million yen. However, the company experienced a decline in operating profit and ordinary profit by 18.0% and 21.7%, respectively. The profit attributable to owners of the parent decreased significantly by 32.4%. Despite these declines, the company has increased its annual dividends per share from 40.00 yen to 55.00 yen, indicating a commitment to returning value to shareholders. Looking forward, ASKA forecasts a positive outlook for FY2025, with expected increases in net sales and profits, reflecting a strategic focus on growth and operational efficiency.

More about ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Pharmaceutical Holdings Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily engaged in the pharmaceutical industry. The company focuses on developing and marketing pharmaceutical products, contributing to healthcare advancements.

Average Trading Volume: 47,952

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen61.9B

For an in-depth examination of 4886 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1